Open Access

Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors

  • Authors:
    • Xiaowei Liu
    • Cheng Cheng
    • Yuanxia Cai
    • Yaoyao Gu
    • Yangkun Wu
    • Kai Chen
    • Zhixiang Wu
  • View Affiliations

  • Published online on: April 14, 2022     https://doi.org/10.3892/ijo.2022.5356
  • Article Number: 66
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Studies have shown that PCNA clamp associated factor (PCLAF) plays a paramount role in a variety of cancers; however, the expression profile and the specific molecular mechanism of PCLAF in cancer remains unclear, as is its value in the human pan‑cancer analysis. Based on the publicly available datasets of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), a comprehensive analysis of the probable carcinogenic effects of the PCLAF gene was performed in 33 human cancers. It was found that PCLAF is highly expressed in cancer tissues compared with normal tissues, and is significantly correlated with poor prognosis. We found that the eight tumors with significantly high PCLAF expression presented with decreased DNA methylation levels of PCLAF, including cholangiocarcinoma (CHOL), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), glioblastoma multiforme (GBM), pheochromocytoma and paraganglioma (PCPG), sarcoma (SARC), testicular germ cell tumor (TGCT), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC). The expression of PCLAF was found to be positively correlated with activated CD4 T cells (Act CD4) and type 2 T helper (Th2) cells, suggesting that PCLAF may play a particular role in tumor immune infiltration. In addition, the functional mechanism of PCLAF also involves the mitotic cell cycle process, cell division, and DNA replication. Our first pan‑cancer study provides a relatively extensive understanding of the carcinogenic effects of PCLAF in miscellaneous tumors.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 60 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu X, Cheng C, Cai Y, Gu Y, Wu Y, Chen K and Wu Z: Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors. Int J Oncol 60: 66, 2022
APA
Liu, X., Cheng, C., Cai, Y., Gu, Y., Wu, Y., Chen, K., & Wu, Z. (2022). Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors. International Journal of Oncology, 60, 66. https://doi.org/10.3892/ijo.2022.5356
MLA
Liu, X., Cheng, C., Cai, Y., Gu, Y., Wu, Y., Chen, K., Wu, Z."Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors". International Journal of Oncology 60.6 (2022): 66.
Chicago
Liu, X., Cheng, C., Cai, Y., Gu, Y., Wu, Y., Chen, K., Wu, Z."Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors". International Journal of Oncology 60, no. 6 (2022): 66. https://doi.org/10.3892/ijo.2022.5356